Overview

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Status:
Completed
Trial end date:
2015-06-19
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
Phase:
Phase 1
Details
Lead Sponsor:
Mirum Pharmaceuticals, Inc.
Shire
Treatments:
Volixibat